168 related articles for article (PubMed ID: 37075248)
1. False-Positive Uptake in Splenic Hemangioma on 68 Ga-DOTATATE PET/CT.
Zhu B; Yoon E; Mahajan S; Kranz AO
Clin Nucl Med; 2023 Jun; 48(6):518-519. PubMed ID: 37075248
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 68 Ga-DOTATATE PET/CT and 68 Ga-Pentixiafor PET/CT Imaging in a Case of Merkel Cell Carcinoma.
Rao Z; Zhang Y; Liu L; Wang M; Zhang C
Clin Nucl Med; 2023 Apr; 48(4):339-341. PubMed ID: 36727900
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
Deppen SA; Liu E; Blume JD; Clanton J; Shi C; Jones-Jackson LB; Lakhani V; Baum RP; Berlin J; Smith GT; Graham M; Sandler MP; Delbeke D; Walker RC
J Nucl Med; 2016 May; 57(5):708-14. PubMed ID: 26769865
[TBL] [Abstract][Full Text] [Related]
4. Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.
Crown A; Rocha FG; Raghu P; Lin B; Funk G; Alseidi A; Hubka M; Rosales J; Lee M; Kennecke H
J Surg Oncol; 2020 Mar; 121(3):480-485. PubMed ID: 31853990
[TBL] [Abstract][Full Text] [Related]
5. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
6. Unusual 68 Ga-DOTATATE Uptake in Primary Nodal Hemangioma of Axillary Lymph Node.
Sariyildiz Gumusgoz H; Burak Z; Karasah Erkek B
Clin Nucl Med; 2022 Sep; 47(9):809-810. PubMed ID: 35353744
[TBL] [Abstract][Full Text] [Related]
7. Head-to-Head Comparison of
Zhu W; Cheng Y; Wang X; Yao S; Bai C; Zhao H; Jia R; Xu J; Huo L
J Nucl Med; 2020 Jun; 61(6):897-903. PubMed ID: 31676731
[No Abstract] [Full Text] [Related]
8. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
9. 68Ga-DOTATATE Uptake in Pancreatic Metastasis of Renal Cell Carcinoma Mimicking Pancreatic Neuroendocrine Tumor.
Soydal C; Nak D; Araz M; Demirkazik A; Kucuk NO
Clin Nucl Med; 2019 Oct; 44(10):795-796. PubMed ID: 31306201
[TBL] [Abstract][Full Text] [Related]
10. Differential Detection of Hepatic Metastases on 68 Ga-DOTATATE PET/CT and 177 Lu-DOTATATE SPECT/CT.
Zahed H; Beauregard JM; Abikhzer G; Rush C; Probst S
Clin Nucl Med; 2023 Jan; 48(1):e12-e15. PubMed ID: 36240803
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
12. Differences in tumor-to-normal organ SUV ratios measured with 68 Ga-DOTATATE PET compared with 177 Lu-DOTATATE SPECT in patients with neuroendocrine tumors.
Wong KK; Frey KA; Niedbala J; Kaza RK; Worden FP; Fitzpatrick KJ; Dewaraja YK
Nucl Med Commun; 2022 Aug; 43(8):892-900. PubMed ID: 35703269
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular Carcinoma Mimicking Neuroendocrine Tumor Metastasis on 68Ga-DOTATATE PET/CT.
Ulaner GA; Bodei L
Clin Nucl Med; 2019 Apr; 44(4):330-331. PubMed ID: 30688738
[TBL] [Abstract][Full Text] [Related]
14. Cardiac hemangioma mimicking a neuroendocrine tumor on
Shah A; Binkovitz L; Layman AJ; Bois MC; Nguyen B
J Card Surg; 2022 Sep; 37(9):2849-2851. PubMed ID: 35502494
[TBL] [Abstract][Full Text] [Related]
15. 68 Ga-PSMA PET/CT in Hepatic Metastasis From Pancreatic Neuroendocrine Tumor.
Chen S; Lin Z; Wang C; Miao W
Clin Nucl Med; 2023 Nov; 48(11):991-993. PubMed ID: 37796174
[TBL] [Abstract][Full Text] [Related]
16. The Correlation Between [
Yu J; Li N; Li J; Lu M; Leal JP; Tan H; Su H; Fan Y; Zhang Y; Zhao W; Zhu H; Pomper MG; Zhou Y; Yang Z
Mol Imaging Biol; 2019 Oct; 21(5):984-990. PubMed ID: 30796708
[TBL] [Abstract][Full Text] [Related]
17. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
Sadowski SM; Neychev V; Millo C; Shih J; Nilubol N; Herscovitch P; Pacak K; Marx SJ; Kebebew E
J Clin Oncol; 2016 Feb; 34(6):588-96. PubMed ID: 26712231
[TBL] [Abstract][Full Text] [Related]
18. A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice.
Aalbersberg EA; Geluk-Jonker MM; Young-Mylvaganan T; de Wit-van der Veen LJ; Stokkel MPM
J Vis Exp; 2019 Apr; (146):. PubMed ID: 31058910
[TBL] [Abstract][Full Text] [Related]
19. Anastomosing Hemangioma on 68Ga-DOTATATE PET/CT: A Potential Pitfall.
Chua WM; Hoe KMJ; Dalan R; Too CW; Ong SYK; Tay TKY; Loke KSH
Clin Nucl Med; 2022 Apr; 47(4):321-323. PubMed ID: 35020655
[TBL] [Abstract][Full Text] [Related]
20. Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management.
Kunikowska J; Lewington V; Krolicki L
Clin Nucl Med; 2017 Dec; 42(12):905-911. PubMed ID: 29076910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
